Federal Register / Vol. 88, No. 237 / Tuesday, December 12, 2023 / Notices 86137 

H.J. Berkley Trust U/A dated 05/06/69, 

and the Robert B. Berkley Trust U/A 

dated 12/01/67, both of Salina, Kansas; 

the Don Berkley Trust No. 2, Don and 

Patricia Berkley, as co-trustees, all of 

Abilene, Kansas; the Jerry J. Berkley 

Trust No. 2, Eleanor A. Berkley and 

Bruce A. Berkley, as co-trustees, all of 

Downs, Kansas, and Cheryl L. Jamison, 

as co-trustee of the aforementioned 

trust, Emporia, Kansas; the Paul D. 

Berkley Trust No. 2, Bill Berkley, as cotrustee, both of Downs, Kansas, Brandon 

Berkley, Denver, Colorado, and Bradley 

Berkley, Dallas, Texas, as co-trustees of 

the aforementioned trust; the Robert B. 

Berkley Family Trust, Lila A. Berkley, as 

co-trustee, both of Salina, Kansas, Lila 

Jean Alexander, Houston, Texas, and 

John A. Berkley, Stockton, Kansas, as 

co-trustees of the aforementioned trust; 

the Hal J. Berkley Trust A and the 

Eleanor L. Berkley Trust, Hal J. Berkley 

and Eleanor L. Berkley, as co-trustees, 

all of Tescott, Kansas; the Karla J. 

Spurgeon Trust II, the Marika Spurgeon 

GP Trust, the Brenna Spurgeon GP 

Trust, and the Patrick Spurgeon GP 

Trust, Karen M. Deckert and Calvin J. 

Berkley, as co-trustees, all of Tescott, 

Kansas, and Jeff A. Berkley, as cotrustee; the Karen M. Deckert Trust II, 

the Samuel Deckert GP Trust, and the 

Lucas Deckert GP Trust, all of Tescott, 

Kansas, Karla J. Spurgeon, Lawrence, 

Kansas, Jeff A. Berkley, and Calvin J. 

Berkley, as co-trustees; the Jeff A. 

Berkley Trust II, the Rebekah Berkley GP 

Trust, and the Rachel Berkley GP Trust, 

all of Tescott, Kansas, Karla J. Spurgeon, 

Karen M. Deckert, and Calvin J. Berkley, 

as co-trustees; the Calvin J. Berkley 

Trust II, the Megan Berkley GP Trust, 

and the Collin Berkley GP Trust, all of 

Tescott, Kansas, Karla J. Spurgeon, 

Karen M. Deckert, and Jeff A. Berkley as 

co-trustees; the Paula C. Nelson Trust 

No. 2, Paula Nelson, as trustee, both of 

Tescott, Kansas; the Mary Beth Phelps 

Trust No. 2, Mary Beth Phelps, as 

trustee, both of Tescott, Kansas; the 

Mark A. Berkley Trust and the Jane B. 

Berkley Trust, Mark A. and Jane B. 

Berkley, as co-trustees, all of Leawood, 

Kansas; Elizabeth E. Berkley, Naples, 

Florida, as co-trustee of the Stuart C. 

Berkley Trust and the Melissa J. Berkley 

Trust, both of Leawood, Kansas; Stuart 

C. Berkley, Prairie Village, Kansas, as 

co-trustee of the Elizabeth E. Berkley 

Trust and the Melissa J. Berkley Trust, 

both of Leawood, Kansas; Melissa 

Ungashick, Overland Park, Kansas, as 

co-trustee of the Stuart C. Berkley Trust 

and the Elizabeth E. Berkley Trust; Earl 

H. Matthews and Burke L. Matthews, 

both of Salina, Kansas; to join the 

Berkley Family Group, a group acting in 

concert, to retain voting shares of 

Tescott Bancshares, Inc., and thereby 

indirectly retain voting shares of The 

Bank of Tescott, both of Tescott, Kansas. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2023–27237 Filed 12–11–23; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Supplemental Evidence and Data 

Request on Systematic Review— 

Interventions To Improve Care of 

Bereaved Persons 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for supplemental 

evidence and data submission. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

the public. Scientific information is 

being solicited to inform our review on 

Systematic Review—Interventions to 

Improve Care of Bereaved Persons, 

which is currently being conducted by 

the AHRQ’s Evidence-based Practice 

Centers (EPC) Program. Access to 

published and unpublished pertinent 

scientific information will improve the 

quality of this review. 

DATES: Submission Deadline on or 

before January 11, 2024. 

ADDRESSES: 

Email submissions: epc@

ahrq.hhs.gov. 

Print submissions: 

Mailing Address: Center for Evidence 

and Practice Improvement, Agency for 

Healthcare Research and Quality, 

ATTN: EPC SEADs Coordinator, 5600 

Fishers Lane, Mail Stop 06E53A, 

Rockville, MD 20857. 

Shipping Address (FedEx, UPS, etc.):, 

Center for Evidence and Practice 

Improvement, Agency for Healthcare 

Research and Quality, ATTN: EPC 

SEADs Coordinator, 5600 Fishers Lane, 

Mail Stop 06E77D, Rockville, MD 

20857. 

FOR FURTHER INFORMATION CONTACT: 

Kelly Carper, Telephone: 301–427–1656 

or Email: epc@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Agency for Healthcare Research and 

Quality has commissioned the 

Evidence-based Practice Centers (EPC) 

Program to complete a review of the 

evidence for Systematic Review— 

Interventions to Improve Care of 

Bereaved Persons. AHRQ is conducting 

this review pursuant to section 902 of 

the Public Health Service Act, 42 U.S.C. 

299a. 

The EPC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by requesting information 

from the public (e.g., details of studies 

conducted). We are looking for studies 

that report on Systematic Review— 

Interventions to Improve Care of 

Bereaved Persons. The entire research 

protocol is available online at: https://

effectivehealthcare.ahrq.gov/products/ 

bereaved-persons/protocol. 

This is to notify the public that the 

EPC Program would find the following 

information on Systematic Review— 

Interventions to Improve Care of 

Bereaved Persons helpful: 

D A list of completed studies that 

your organization has sponsored for this 

topic. In the list, please indicate 

whether results are available on 

ClinicalTrials.gov along with the 

ClinicalTrials.gov trial number. 

D For completed studies that do not 

have results on ClinicalTrials.gov, a 

summary, including the following 

elements, if relevant: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to follow-up/withdrawn/ 

analyzed, effectiveness/efficacy, and 

safety results. 

D A list of ongoing studies that your 

organization has sponsored for this 

topic. In the list, please provide the 

ClinicalTrials.gov trial number or, if the 

trial is not registered, the protocol for 

the study including, if relevant, a study 

number, the study period, design, 

methodology, indication and diagnosis, 

proper use instructions, inclusion and 

exclusion criteria, and primary and 

secondary outcomes. 

D Description of whether the above 

studies constitute ALL Phase II and 

above clinical trials sponsored by your 

organization for this topic and an index 

outlining the relevant information in 

each submitted file. 

Your contribution is very beneficial to 

the Program. Materials submitted must 

be publicly available or able to be made 

public. Materials that are considered 

confidential; marketing materials; study 

types not included in the review; or 

information on topics not included in 


ddrumheller on DSK120RN23PROD with NOTICES1
86138 Federal Register / Vol. 88, No. 237 / Tuesday, December 12, 2023 / Notices 

the review cannot be used by the EPC 

Program. This is a voluntary request for 

information, and all costs for complying 

with this request must be borne by the 

submitter. 

The draft of this review will be posted 

on AHRQ’s EPC Program website and 

available for public comment for a 

period of 4 weeks. If you would like to 

be notified when the draft is posted, 

please sign up for the email list at: 

https://www.effectivehealthcare

.ahrq.gov/email-updates. 

The review will answer the following 

questions. This information is provided 

as background. AHRQ is not requesting 

that the public provide answers to these 

questions. 

Key Questions (KQ) 

Key Question 1: What is the 

effectiveness and harms of universally 

screening people for bereavement and 

response to loss? 

a. Timing: predeath, acute, or 6–12 

months post loss, and more than 1 year 

post loss? 

b. Does effectiveness vary by patient 

characteristic or setting? 

Key Question 2: How accurate are 

tools to identify bereaved persons at risk 

for or with grief disorders? 

Key Question 3: What are the 

effectiveness, comparative effectiveness, 

and harms of interventions for people at 

risk for grief disorders related to 

bereavement? 

a. Timing: predeath, acute, or 6–12 

months post loss, and more than 1 year 

post loss? 

b. Does effectiveness vary by patient 

characteristic or setting? 

Key Question 4: What are the 

effectiveness, comparative effectiveness 

and harms of interventions for people 

diagnosed with grief-related disorders? 

a. Does effectiveness vary by patient 

characteristic or setting? 

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING) ELIGIBILITY CRITERIA

Element Inclusion criteria Exclusion criteria 

Population .............. KQ1: Children or adults .......................................................................

KQ2–3: Children or adults who have experienced a human (including in utero) death of someone close to them or will do so in the 

near future (e.g., in a hospice setting) and who are at risk of 

being diagnosed with a grief disorder.

KQ4: Children or adults diagnosed with a grief disorder (prolonged 

grief disorder, complicated grief, chronic grief disorder, persistent 

complex bereavement disorder) according to DSM (prolonged 

grief disorder) or ICD (ICD11 6B42, ICD10 F43.81, ICD9 309.0).

Studies on other forms than personal grief, such as 

community expressions of grief, public reactions 

to loss or trauma. 

Interventions ........... KQ1: Screening strategy evaluation with screening tool .....................

KQ2: Diagnostic strategy evaluation, diagnostic or screening tool .....

KQ3: Interventions to prevent or treat grief disorder ...........................

KQ4: Interventions to treat grief disorders ..........................................

KQ1: Incidental or non-systematic identification of 

grief or reaction to loss. 

KQ3:–4: Interventions delivered by lay persons or 

non-healthcare professionals not applicable to a 

healthcare setting. 

Comparators ........... KQ1: No screening approach, usual care, or an alternative screening approach.

KQ2: No tool, an alternative tool, concordance with grief disorder diagnosis.

KQ3: No intervention, usual care, or an alternative intervention ........

KQ4: Usual care or an alternative intervention ...................................

KQ1: No reference standard or method to detect 

the impact of screening. 

KQ2: No reference standard to determine the accuracy of the diagnostic tool. 

KQ3:–4: No concurrent comparator. 

Outcomes ............... KQ1: Immediate experience (patient experience, medicalizing grief, 

abnormalizing grief, feeling of pathologizing a normal process), 

screening accuracy (e.g., correctly diagnosed with grief disorder), 

and impact (e.g., delayed diagnosis, underdiagnosis, overdiagnosis, delayed treatment, undertreatment due to missed diagnosis, overtreatment).

KQ2: Diagnostic accuracy (e.g., sensitivity, specificity, accuracy, 

area under the curve, positive predictive value, negative predictive 

value, false positives, false negatives, grief disorder identification) 

or impact (e.g., delayed diagnosis, underdiagnosis, overdiagnosis, 

effects of false positive test results, delayed treatment, undertreatment due to missed diagnosis, overtreatment).

KQ3: Grief symptoms, incidence of grief disorder, severity of grief 

disorder, any adverse events or unintended consequences of the 

intervention.

KQ4: Grief symptoms, resolution of grief disorder diagnosis, physical 

or mental health, quality of life, functional status, patient experience, costs, any adverse events or unintended consequences of 

the intervention.

Clinician or organizational barriers to, opinions on, 

preferences to, or uptake of screening, diagnosing, or treatment of grief. 

Timing ..................... Any, no restrictions regarding the timing of the intervention or follow 

up.

Setting .................... Any setting.

Study Design .......... KQ1:–2: Screening and diagnosis impact analyses and diagnostic 

accuracy studies.

KQ3:–4: Randomized controlled trials (RCTs), clinical trials comparing two or more interventions, observational cohort studies 

comparing two or more intervention cohorts, controlled post-only 

studies, and case-control studies.

KQ1:–2: Descriptions without information on the 

impact or accuracy of the screening approach or 

tool performance. 

KQ3:–4: Studies without control group or concurrent group that does not receive the intervention 

or that receives a different intervention. 

Other limiters .......... Data published in English-language journal manuscript or trial 

records; relevant literature reviews will be retained for reference 

mining.

Data only reported in abbreviated format (e.g., conference abstracts) and/or data only reported in 

non-English outlets. 

Notes: DSM Diagnostic and Statistical Manual of Mental Disorders, ICD international classification of diseases, KQ key question. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 237 / Tuesday, December 12, 2023 / Notices 86139 

Dated: December 7, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–27238 Filed 12–11–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, Office 

of Readiness and Response 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting for the 

Board of Scientific Counselors, Office of 

Readiness and Response (BSC, ORR). 

This virtual meeting is open to the 

public, limited only by the number of 

web conference lines available (500 

lines). Registration in advance is 

required by accessing the link below in 

the addresses section. Time will be 

available for public comment. 

DATES: The meeting will be held on 

January 25, 2024, from 9 a.m. to 4:30 

p.m., EST, and January 26, 2024, from 

9 a.m. to 12 p.m., EST. 

ADDRESSES: Zoom virtual meeting. If 

you wish to attend the meeting, please 

register in advance by accessing the link 

at https://cdc.zoomgov.com/webinar/ 

register/WN_OHYkxlt_

QNyys3kLsfQ3Wg#/registration. 

Instructions to access the meeting will 

be provided following registration. 

FOR FURTHER INFORMATION CONTACT: 

Dometa Ouisley, Public Health Analyst, 

Office of Science and Laboratory 

Readiness, Office of Readiness and 

Response, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H21–6, Atlanta, Georgia 

30329–4027. Telephone: (404) 639– 

7450; Email: DOuisley@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Board of Scientific 

Counselors, Office of Readiness and 

Response provides advice and guidance 

to the Secretary, Department of Health 

and Human Services (HHS); the 

Assistant Secretary for Health, HHS; the 

Director, Centers for Disease Control 

and Prevention (CDC); and the Director, 

Office of Readiness and Response 

(ORR), CDC. The Board recommends 

strategies and goals for readiness and 

response activities pertaining to 

programs and research within the 

agency and the ORR divisions and 

monitors the overall strategic direction 

and focus of the ORR divisions and 

offices. The Board also provides 

administration and oversight of peer 

review for ORR scientific programs. For 

additional information about the Board, 

please visit https://www.cdc.gov/orr/ 

bsc/index.htm. 

Matters to be Considered: Agenda 

topics for Day 1 will include: (1) 

Organizational Update, (2) Division of 

Readiness and Response Science 

Overview, (3) Division Directors 

Updates, and (4) Discussion: Growing 

Science and Science Strategies. Agenda 

topics for Day 2 will include: (1) Polio 

Containment Working Group Updates, 

(2) Health Equity Working Group 

Updates, and (3) Discussion: Improving 

Readiness for Future Threats. Agenda 

items are subject to change as priorities 

dictate. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–27170 Filed 12–11–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Structural Biophysics. 

Date: December 20, 2023. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dennis Pantazatos, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–2381, dennis.pantazatos@

nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 7, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–27198 Filed 12–11–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group Career 

Development Education and Training Study 

Section. 

Date: February 23, 2024. 

Time: 9:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sindhu Kizhakke 

Madathil, Ph.D., Scientific Review Officer, 


ddrumheller on DSK120RN23PROD with NOTICES1